What a development-ready generic drug dossier actually contains
A generic company that wants to copy a marketed product normally starts from scratch: months of excipient screening, process trials, and dissolution tuning before the first bioequivalence batch exists. A development-ready dossier compresses that phase into a package that arrives before the lab work begins - the formula, the procedure, the specifications, and the evidence that it should behave like the reference.
The four parts / what regulators and licensees check
The quantitative recipe: every excipient, its grade, supplier class, and percentage by weight, per unit and per batch. For a tablet this means the binder, filler, disintegrant, lubricant, glidant, and coating system - each resolved to the level a purchasing department can order and a formulator can weigh. Where public records leave a value uncertain, a defensible range is given instead of a false precision.
The process that produces the formula on real equipment: unit operations, critical process parameters, in-process controls, and scale-up notes. A dossier that only lists ingredients without the process is a catalog, not a recipe - the same formula can pass or fail depending on how it is made.
The acceptance criteria for the API, excipients, and finished product: assay, impurities, dissolution, uniformity, physical properties. These anchor the formula to what regulators already accepted for the reference product, in the compendial terms an ANDA or 505(b)(2) filing will restate.
The argument that the candidate behaves like the reference: dissolution profiles compared against the reference product across compendial media, similarity statistics, and - where the technology allows - a simulation package estimating in vivo exposure before a pilot bioequivalence study.
Where it sits in an ANDA or 505(b)(2) program
An ANDA requires demonstrated sameness: same active ingredient, dosage form, route, and strength as the reference listed drug, plus bioequivalence in vivo. A 505(b)(2) allows differences where the applicant can bridge them with data. In both paths the formulation work is upstream of the bioequivalence study - and it is the stage where most programs lose time, because a failed BE study sends development back to formulation.
A dossier is not a substitute for the licensee's own development and regulatory work: the filing, the exhibit batches, the BE study, and the site transfer still belong to the licensee. What the dossier removes is the most uncertain phase - reaching a formula and process that deserve to be tested - so the licensee spends its development budget confirming a strong candidate instead of searching for one.
| Stage | Dossier provides | Licensee provides |
|---|---|---|
| Candidate formula + process | Master formula, procedure, CPPs, specs | Site fit, sourcing, GMP transfer |
| Pre-formulation evidence | Provenance map, dissolution rationale, simulations | Independent verification, lab confirmation |
| First development batch | Recommended batch design and test plan | Manufacture, testing, deviations |
| Bioequivalence + filing | Study-design appendix, prior evidence | Clinical conduct, ANDA/505(b)(2) submission |